Semnur Pharmaceuticals Inc (SMNR)
Health CareSnapshot 2026-11-04
$0.50-9.02%
Close 2026-09-04 · 1-day change
Health CareSnapshot 2026-11-04
QuarterlyIQ Insights · SMNR
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|---|
| Operating Expenses & Income | |||||
| R&D Expenses | 4.7 | 2.5 | — | — | — |
| Operating Income | (18.5) | (160.4) | (1.6) | (3.2) | — |
| Earnings from Continuing Operations | |||||
| Interest Expense | — | — | 0.1 | 0.0 | — |
| Interest & Investment Income | — | — | 1.6 | 3.8 | 1.2 |
| Net Interest Expenses | — | — | — | (3.8) | — |
| Net Income | |||||
| Net Income | (18.7) | (160.4) | (0.2) | 0.6 | (0.4) |
| Per Share | |||||
| Basic EPS | (0.08) | (0.78) | — | — | — |
| Diluted EPS | (0.08) | (0.78) | — | — | — |
| Basic Weighted Avg Shares | 224.2 | 204.8 | — | — | — |
| Diluted Weighted Avg Shares | 224.2 | 204.8 | — | — | — |
| Supplemental | |||||
| EBIT | (18.5) | (160.4) | (1.6) | (3.2) | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.